Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Sep 21, 2005; 11(35): 5540-5544
Published online Sep 21, 2005. doi: 10.3748/wjg.v11.i35.5540
Published online Sep 21, 2005. doi: 10.3748/wjg.v11.i35.5540
Table 2 Adverse events (n = 26) leading to discontinuation of 6-TG use in 20 patients (AE, adverse event; 6-TG, 6-thioguanine; GI complaints, gastrointestinal complaints)
| AE on 6-TG | Frequency (%) | Mean time to AE (d) | Relationship with 6-TG |
| GI complaints | 8/26 (31) | 43 | Probably 6/8 possibly 2/8 |
| Hepatotoxicity | 4/26 (15) | 182 | Probably 2/4 possibly ¼unrelated 1/4 |
| Myelodepression | 1/26 (4) | 50 | Related |
| Pancreaticotoxicity | 1/26 (4) | 103 | Possibly |
| General malaise | 4/26 (15) | 51 | Probably 3/4 possibly ¼ |
| Allergic reaction | 1/26 (4) | 1 | Related |
| Other AE | 7/26 (27) | 39 | Related 1/7 probably |
| 2/7 possibly 4/7 |
- Citation: Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, Boer SY, Hartog GD, Hooymans PM, Mäkelburg AB, Westerveld BD, Naber AH, Mulder CJ, Jong DJ. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 2005; 11(35): 5540-5544
- URL: https://www.wjgnet.com/1007-9327/full/v11/i35/5540.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i35.5540